Biotech & MedTech News
-
Hemostemix Announces Exploring Clinical Trial Financing Alternatives
October 4, 2022 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) (“Hemostemix” or the “Company”) is pleased…
-
Hemostemix Announces the Appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to Its Scientific Advisory Board
September 27, 2022 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) (“Hemostemix” or the “Company”) is pleased…
-
Zentek’s ZenGUARD(TM) Patent Application Allowed by the Canadian Patent Office
September 27, 2022 (Source) – Zentek Ltd. (“Zentek” or the “Company”) (NASDAQ:ZTEK); (TSXV:ZEN), an intellectual property (IP) development and commercialization…
-
Voyageur Pharmaceuticals Ltd. Submits Notice of Work to Extract 2,000 Tonnes of Barium Sulfate from Frances Creek Project
September 22, 2022 (Source) — Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the “Company” or “Voyageur”) has submitted a notice of work…
-
Hemostemix Announces the Appointment of Dr. Terry Hébert, PhD, to Its Scientific Advisory Board
September 20, 2022 (Source) — Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) (“Hemostemix” or the “Company”) is pleased…
-
Zentek To Present at Sidoti Small-Cap Virtual Conference
September 20, 2022 (Source) — Zentek Ltd. (“Zentek” or the “Company”) (NASDAQ:ZTEK)(TSX-V:ZEN), an intellectual property development and commercialization company, announces…
-
Hemostemix Announces the Appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board
September 16, 2022 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) (“Hemostemix” or the “Company”) is pleased to…
-
Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board
September 15, 2022 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (“Hemostemix” or the “Company”) is pleased to announce the…
-
Zentek Provides Update on HVAC Testing
September 15, 2022 (Source) – Zentek Ltd. (“Zentek” or the “Company”) (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property development and commercialization company, reports,…
-
Awakn Life Sciences Reports Strong Q2 2022 Results
Awakn delivered revenue growth of 34% in Q2 Awakn also announces closing of first tranche of private placement…
